- About
- Advertise
- CureToday.com
- OncLive.com
- OncNursingNews.com
- TargetedOnc.com
- Contact
- Terms and Conditions
- Privacy
- Do Not Sell My Personal Information
© 2022 MJH Life Sciences™ and Cancer Network. All rights reserved.
Sarah M. Tolaney, MD, MPH | Authors
Exciting Developments in the HER2+ Breast Cancer Treatment Landscape
May 18, 2022
Sarah M. Tolaney, MD, MPH, highlights recent and investigative treatments for HER2+ breast cancer that excite her and provides some clinical pearls for community oncologists.
The Role of Maintenance Therapy in HER2+ Breast Cancer
May 18, 2022
Dr Sarah M. Tolaney discusses whether maintenance therapy has a role in HER2+ breast cancer treatment.
Discussing Treatment Decisions with Patients with Early-Stage HER2+ Breast Cancer
May 18, 2022
A key opinion leader explains how she discusses treatment options and trial data with patients with early stage HER2+ breast cancer.
Subcutaneous Treatment of Early-Stage HER2+ Breast Cancer During the COVID-19 Pandemic
May 11, 2022
Sarah M. Tolaney, MD, MPH, describes her usage of pertuzumab, trastuzumab, and hyaluronidase-zzxf subcutaneous injections in her clinical practice during the COVID-19 pandemic for patients with HER2+ breast cancer.
Subcutaneous Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf Injections for Early-Stage HER2+ Breast Cancer
May 11, 2022
An expert oncologist explains the combination subcutaneous injection therapy of pertuzumab, trastuzumab, and hyaluronidase-zzxf for patients with early-stage HER2+ breast cancer.
Frontline Treatment Options for Early-Stage HER2+ Breast Cancer
May 06, 2022
Sarah M. Tolaney, MD, MPH, reviews the treatment options for patients with early-stage HER2+ breast cancer in the frontline setting.
Goals of Care for Patients with Early-Stage versus Advanced or Metastatic HER2+ Breast Cancer
May 06, 2022
Sarah M. Tolaney, MD, MPH, provides an overview of how goals of care and prognosis differ between patients with early-stage HER2+ breast cancer and advanced or metastatic HER2+ breast cancer.